Connor, Clark & Lunn Investment Management (CC&L)’s Biogen BIIB Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $853K | Buy |
+3,948
| New | +$755K | ﹤0.01% | 1238 |
|
|
2025
Q4 | – | Sell |
-116,928
| Closed | -$16.4M | – | 1545 |
|
|
2025
Q3 | $16.4M | Sell |
116,928
-100,810
| -46% | -$13.6M | 0.05% | 306 |
|
|
2025
Q2 | $27.3M | Sell |
217,738
-60,096
| -22% | -$7.49M | 0.1% | 185 |
|
|
2025
Q1 | $38M | Buy |
277,834
+137,514
| +98% | +$19.7M | 0.17% | 107 |
|
|
2024
Q4 | $21.5M | Buy |
140,320
+117,576
| +517% | +$19.8M | 0.1% | 165 |
|
|
2024
Q3 | $4.41M | Sell |
22,744
-65,758
| -74% | -$13.8M | 0.02% | 469 |
|
|
2024
Q2 | $20.5M | Buy |
88,502
+76,465
| +635% | +$16.6M | 0.09% | 183 |
|
|
2024
Q1 | $2.6M | Buy |
+12,037
| New | +$2.82M | 0.01% | 607 |
|
|
2023
Q3 | – | Sell |
-54,037
| Closed | -$15.4M | – | 1367 |
|
|
2023
Q2 | $15.4M | Sell |
54,037
-53,231
| -50% | -$15.8M | 0.08% | 193 |
|
|
2023
Q1 | $29.8M | Buy |
107,268
+45,041
| +72% | +$12.5M | 0.16% | 111 |
|
|
2022
Q4 | $17.2M | Buy |
+62,227
| New | +$17.6M | 0.1% | 160 |
|
|
2022
Q2 | – | Sell |
-11,787
| Closed | -$2.48M | – | 1047 |
|
|
2022
Q1 | $2.48M | Buy |
11,787
+4,899
| +71% | +$1.07M | 0.01% | 453 |
|
|
2021
Q4 | $1.65M | Sell |
6,888
-1,690
| -20% | -$435K | 0.01% | 580 |
|
|
2021
Q3 | $2.43M | Sell |
8,578
-7,463
| -47% | -$2.45M | 0.01% | 486 |
|
|
2021
Q2 | $5.55M | Sell |
16,041
-15,648
| -49% | -$4.74M | 0.03% | 333 |
|
|
2021
Q1 | $8.87M | Sell |
31,689
-58,936
| -65% | -$15.9M | 0.05% | 256 |
|
|
2020
Q4 | $22.2M | Buy |
90,625
+55,751
| +160% | +$14.4M | 0.13% | 135 |
|
|
2020
Q3 | $9.89M | Sell |
34,874
-35,751
| -51% | -$9.97M | 0.07% | 200 |
|
|
2020
Q2 | $18.9M | Buy |
70,625
+34,478
| +95% | +$10.4M | 0.13% | 131 |
|
|
2020
Q1 | $11.4M | Sell |
36,147
-32,530
| -47% | -$9.87M | 0.1% | 140 |
|
|
2019
Q4 | $20.4M | Sell |
68,677
-36,248
| -35% | -$10.1M | 0.14% | 121 |
|
|
2019
Q3 | $24.4M | Sell |
104,925
-39,775
| -27% | -$9.26M | 0.17% | 109 |
|
|
2019
Q2 | $33.8M | Buy |
144,700
+52,825
| +57% | +$12.2M | 0.22% | 87 |
|
|
2019
Q1 | $21.7M | Buy |
91,875
+81,275
| +767% | +$25.6M | 0.14% | 120 |
|
|
2018
Q4 | $3.19M | Sell |
10,600
-23,700
| -69% | -$7.56M | 0.02% | 341 |
|
|
2018
Q3 | $12.1M | Buy |
34,300
+13,150
| +62% | +$4.53M | 0.07% | 196 |
|
|
2018
Q2 | $6.14M | Sell |
21,150
-9,500
| -31% | -$2.67M | 0.03% | 286 |
|
|
2018
Q1 | $8.39M | Buy |
30,650
+15,500
| +102% | +$4.81M | 0.05% | 224 |
|
|
2017
Q4 | $4.83M | Buy |
15,150
+3,025
| +25% | +$970K | 0.03% | 293 |
|
|
2017
Q3 | $3.8M | Buy |
12,125
+450
| +4% | +$133K | 0.02% | 333 |
|
|
2017
Q2 | $3.17M | Sell |
11,675
-125
| -1% | -$33.1K | 0.02% | 327 |
|
|
2017
Q1 | $3.23M | Buy |
11,800
+1,800
| +18% | +$509K | 0.02% | 314 |
|
|
2016
Q4 | $2.84M | Buy |
10,000
+300
| +3% | +$88.9K | 0.02% | 327 |
|
|
2016
Q3 | $3.04M | Sell |
9,700
-27,775
| -74% | -$8.23M | 0.02% | 309 |
|
|
2016
Q2 | $9.06M | Sell |
37,475
-39,325
| -51% | -$10.4M | 0.07% | 172 |
|
|
2016
Q1 | $20M | Buy |
76,800
+6,525
| +9% | +$1.72M | 0.15% | 104 |
|
|
2015
Q4 | $21.5M | Sell |
70,275
-3,500
| -5% | -$1.01M | 0.18% | 82 |
|
|
2015
Q3 | $21.5M | Buy |
+73,775
| New | +$24.4M | 0.17% | 81 |
|
|
2014
Q4 | – | Sell |
-8,500
| Closed | -$2.81M | – | 582 |
|
|
2014
Q3 | $2.81M | Buy |
8,500
+2,700
| +47% | +$890K | 0.02% | 184 |
|
|
2014
Q2 | $1.95M | Buy |
5,800
+4,600
| +383% | +$1.38M | 0.01% | 248 |
|
|
2014
Q1 | $405K | Sell |
1,200
-22,078
| -95% | -$7.01M | ﹤0.01% | 518 |
|
|
2013
Q4 | $6.92M | Buy |
23,278
+3,828
| +20% | +$990K | 0.05% | 131 |
|
|
2013
Q3 | $4.81M | Buy |
19,450
+13,000
| +202% | +$2.91M | 0.04% | 111 |
|
|
2013
Q2 | $1.46M | Buy |
+6,450
| New | +$1.38M | 0.01% | 224 |
|
Other funds holding BIIB
Connor, Clark & Lunn Investment Management (CC&L)'s BIIB Position: Q2 2026 in Review
Connor, Clark & Lunn Investment Management (CC&L) opened a new position in Biogen (BIIB) in Q2 2026: 3,948 shares worth $853K. The stake represents ﹤0.01% of the portfolio and ranks #1238 among its holdings. This is a return to the name: Connor, Clark & Lunn Investment Management (CC&L) previously reported a position in BIIB as recently as Q3 2025.
Connor, Clark & Lunn Investment Management (CC&L) first reported a position in BIIB in Q2 2013 and has held it in 44 quarters since. The position peaked at $38M in Q1 2025. 1,046 funds tracked by Wall St. Rank hold BIIB as of Q2 2026.
- Connor, Clark & Lunn Investment Management (CC&L) held 3,948 shares of Biogen worth $853K as of Q2 2026.
- Biogen was a new Connor, Clark & Lunn Investment Management (CC&L) position in Q2 2026.
- Biogen made up ﹤0.01% of Connor, Clark & Lunn Investment Management (CC&L)'s portfolio in Q2 2026, its #1238 holding.
- Connor, Clark & Lunn Investment Management (CC&L) first reported a position in Biogen in Q2 2013 and has held it in 44 quarters since.
- Connor, Clark & Lunn Investment Management (CC&L)'s Biogen position peaked at $38M in Q1 2025.
- 1,046 funds tracked by Wall St. Rank held Biogen as of Q2 2026.
Based on Connor, Clark & Lunn Investment Management (CC&L)'s 13F filing for Q2 2026, filed 13 Aug 2026.